Xeris Biopharma Reports Cortisol Normalization With Recorlev in Cushing's Syndrome Case Study
Xeris Biopharma announced a Recorlev case study showing normalized cortisol levels with improved cardiometabolic health in a patient with difficult-to-control diabetes. The case study is scheduled for presentation at the Cardiometabolic Health Congress on October 15-16, 2026. Gvoke research presented October 9, 2026, found a gap between clinicians’ awareness of ready-to-use glucagon prescribing guidelines and actual prescribing practices. A real-world analysis characterizing hypothyroidism patients using levothyroxine treatment records and thyroid laboratory data will be presented November 6, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via (Ref. ID: 202610150800BIZWIRE_USPR_____20261015_BW322412) on October 15, 2026, and is solely responsible for the information contained therein. (C)
Xeris Biopharma announced a Recorlev case study showing normalized cortisol levels with improved cardiometabolic health in a patient with difficult-to-control diabetes. The case study is scheduled for presentation at the Cardiometabolic Health Congress on October 15-16, 2026. Gvoke research presented October 9, 2026, found a gap between clinicians’ awareness of ready-to-use glucagon prescribing guidelines and actual prescribing practices. A real-world analysis characterizing hypothyroidism patients using levothyroxine treatment records and thyroid laboratory data will be presented November 6, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via (Ref.
ID: 202610150800BIZWIRE_USPR_____20261015_BW322412) on October 15, 2026, and is solely responsible for the information contained therein. (C)